RS59358B1 - Nukleotid dims0-150 za upotrebu u tretmanu hroničnog aktivnog ulcerativnog kolitisa - Google Patents
Nukleotid dims0-150 za upotrebu u tretmanu hroničnog aktivnog ulcerativnog kolitisaInfo
- Publication number
- RS59358B1 RS59358B1 RSP20191190A RS59358B1 RS 59358 B1 RS59358 B1 RS 59358B1 RS P20191190 A RSP20191190 A RS P20191190A RS 59358 B1 RS59358 B1 RS 59358B1
- Authority
- RS
- Serbia
- Prior art keywords
- dims0
- nucleotide
- treatment
- ulcerative colitis
- chronic active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11190826.5A EP2596806A1 (en) | 2011-11-25 | 2011-11-25 | Method for prevention of colectomy |
| US201261595230P | 2012-02-06 | 2012-02-06 | |
| EP12790904.2A EP2782602B1 (en) | 2011-11-25 | 2012-11-23 | Nucleotide DIMS0-150 for use in the treatment of chronic active ulcerative colitis |
| PCT/EP2012/073501 WO2013076262A1 (en) | 2011-11-25 | 2012-11-23 | Method for prevention of colectomy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS59358B1 true RS59358B1 (sr) | 2019-11-29 |
Family
ID=45094516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP20191190 RS59358B1 (sr) | 2011-11-25 | 2012-11-23 | Nukleotid dims0-150 za upotrebu u tretmanu hroničnog aktivnog ulcerativnog kolitisa |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9492516B2 (sr) |
| EP (3) | EP2596806A1 (sr) |
| JP (2) | JP6193248B2 (sr) |
| CA (1) | CA2892203C (sr) |
| CY (1) | CY1122089T1 (sr) |
| DK (1) | DK2782602T3 (sr) |
| ES (1) | ES2745677T3 (sr) |
| HR (1) | HRP20191723T1 (sr) |
| HU (1) | HUE046154T2 (sr) |
| LT (1) | LT2782602T (sr) |
| PL (1) | PL2782602T3 (sr) |
| PT (1) | PT2782602T (sr) |
| RS (1) | RS59358B1 (sr) |
| SI (1) | SI2782602T1 (sr) |
| WO (1) | WO2013076262A1 (sr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2879349B1 (en) * | 2013-07-05 | 2022-06-29 | Saturn Licensing LLC | Transmission device, transmission method, reception device and reception method |
| EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
| IL269970B (en) | 2017-04-14 | 2022-09-01 | Tallac Therapeutics Inc | Polynucleotides that modulate the immune system, their antibody binding, and methods of using them |
| GB201707503D0 (en) * | 2017-05-10 | 2017-06-21 | Index Pharmaceuticals Ab | New Therapy 3 |
| GB201707501D0 (en) * | 2017-05-10 | 2017-06-21 | Index Pharmaceuticals Ab | New therapy 2 |
| GB201807312D0 (en) * | 2018-05-03 | 2018-06-20 | Index Pharmaceuticals Ab | Formulation |
| GB201818579D0 (en) * | 2018-11-14 | 2018-12-26 | Index Pharmaceuticals Ab | New therapy |
| GB201912191D0 (en) * | 2019-08-24 | 2019-10-09 | Index Pharmaceuticals Ab | New therapy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| US5849719A (en) | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
| ES2366201T3 (es) | 1994-07-15 | 2011-10-18 | University Of Iowa Research Foundation | Oligonucleótidos inmunmoduladores. |
| DE69739515D1 (de) | 1996-01-30 | 2009-09-10 | Univ California | Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung. |
| ES2241042T3 (es) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| ATE370740T1 (de) | 1997-05-20 | 2007-09-15 | Ottawa Health Research Inst | Verfahren zur herstellung von nukleinsäurekonstrukten |
| US6809193B2 (en) * | 1997-08-13 | 2004-10-26 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US7914990B2 (en) | 2005-01-13 | 2011-03-29 | Progenika Biopharma, S.A. | Methods and products for in vitro genotyping |
| WO2006132204A1 (ja) * | 2005-06-06 | 2006-12-14 | Anges Mg, Inc. | 転写因子デコイ |
| DK2269622T3 (en) | 2005-07-01 | 2014-03-24 | Index Pharmaceuticals Ab | CPG OLIGONUCLEOTIDES USED TO INCREASE STEROID ACTIVITY OF A STEROID DEPENDENT PATIENT |
| DK2179737T3 (da) | 2005-07-01 | 2013-11-11 | Index Pharmaceuticals Ab | Modulering af respons på steroider |
| WO2010053435A2 (en) * | 2008-11-04 | 2010-05-14 | Index Pharmaceuticals Ab | Compounds and methods for the treatment of inflammatory diseases of the cns |
-
2011
- 2011-11-25 EP EP11190826.5A patent/EP2596806A1/en not_active Withdrawn
-
2012
- 2012-11-23 WO PCT/EP2012/073501 patent/WO2013076262A1/en active Application Filing
- 2012-11-23 ES ES12790904T patent/ES2745677T3/es active Active
- 2012-11-23 PL PL12790904T patent/PL2782602T3/pl unknown
- 2012-11-23 RS RSP20191190 patent/RS59358B1/sr unknown
- 2012-11-23 LT LTEP12790904.2T patent/LT2782602T/lt unknown
- 2012-11-23 EP EP12790904.2A patent/EP2782602B1/en active Active
- 2012-11-23 CA CA2892203A patent/CA2892203C/en active Active
- 2012-11-23 DK DK12790904.2T patent/DK2782602T3/da active
- 2012-11-23 PT PT127909042T patent/PT2782602T/pt unknown
- 2012-11-23 US US14/359,945 patent/US9492516B2/en active Active
- 2012-11-23 HU HUE12790904A patent/HUE046154T2/hu unknown
- 2012-11-23 SI SI201231671T patent/SI2782602T1/sl unknown
- 2012-11-23 JP JP2014542858A patent/JP6193248B2/ja active Active
- 2012-11-23 EP EP19173912.7A patent/EP3556403A1/en active Pending
-
2016
- 2016-09-14 US US15/264,709 patent/US9795627B2/en active Active
- 2016-11-08 JP JP2016218270A patent/JP6318221B2/ja active Active
-
2017
- 2017-09-21 US US15/711,228 patent/US20180015117A1/en not_active Abandoned
-
2019
- 2019-09-24 HR HRP20191723 patent/HRP20191723T1/hr unknown
- 2019-09-26 CY CY20191101013T patent/CY1122089T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2782602B1 (en) | 2019-06-26 |
| US9795627B2 (en) | 2017-10-24 |
| EP2596806A1 (en) | 2013-05-29 |
| JP2015504438A (ja) | 2015-02-12 |
| PL2782602T3 (pl) | 2019-12-31 |
| CY1122089T1 (el) | 2020-11-25 |
| HUE046154T2 (hu) | 2020-02-28 |
| JP2017061508A (ja) | 2017-03-30 |
| US20150004187A1 (en) | 2015-01-01 |
| CA2892203C (en) | 2021-11-16 |
| LT2782602T (lt) | 2019-10-10 |
| ES2745677T3 (es) | 2020-03-03 |
| JP6193248B2 (ja) | 2017-09-06 |
| JP6318221B2 (ja) | 2018-04-25 |
| HRP20191723T1 (hr) | 2019-12-13 |
| DK2782602T3 (da) | 2019-09-30 |
| EP3556403A1 (en) | 2019-10-23 |
| US20180015117A1 (en) | 2018-01-18 |
| CA2892203A1 (en) | 2013-05-30 |
| EP2782602A1 (en) | 2014-10-01 |
| PT2782602T (pt) | 2019-10-14 |
| US20170014442A1 (en) | 2017-01-19 |
| US9492516B2 (en) | 2016-11-15 |
| SI2782602T1 (sl) | 2019-11-29 |
| WO2013076262A1 (en) | 2013-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2484598B (en) | Improvements in catheters | |
| ZA201307797B (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| LT2782602T (lt) | Nukleotidas dims0-150, skirtas lėtinio aktyvaus opinio kolito gydymui | |
| HK1198133A1 (en) | Crizotinib for use in the treatment of cancer | |
| GB2487248B (en) | Water treatment | |
| HK1210585A1 (en) | Alpha-1-microglobulin for use in the treatment of mitochondria- related diseases -1 | |
| GB2487246B (en) | Water treatment | |
| GB2487247B (en) | Water treatment | |
| HRP20180011T1 (hr) | Spojevi za uporabu u liječenju filariaza | |
| HK1195331A1 (zh) | 具有高光催化性和清潔性作用的表面處理劑 | |
| ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| GB201110781D0 (en) | Liquid treatment systems | |
| HK1199729A1 (en) | Aldh-2 inhibitors in the treatment of addiction aldh-2 | |
| ZA201307760B (en) | Treatment regimens | |
| PL2734634T3 (pl) | Igf-1 do zastosowania do leczenia migreny | |
| GB2487249B (en) | Water treatment | |
| ZA201406351B (en) | Combination treatment (eg. with abt-072 or abt -333) of daaas for use in theating hvc | |
| GB201116411D0 (en) | Water treatment | |
| GB201116410D0 (en) | Water treatment | |
| GB201121044D0 (en) | Treatment of solutions | |
| GB201113479D0 (en) | Finishing treatment | |
| EP2788292A4 (en) | FLUID TREATMENT SYSTEM |